High Serum Level of Antithymocyte Globulin Immediately before Graft Infusion Is Associated with a Low Likelihood of Chronic, But Not Acute, Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 8, 2014, Pages 1156-1162

  Chawla, Sumit ^a,b   Dharmani Khan, Poonam ^a   Liu, Yiping ^a   Prokopishyn, Nicole ^a   Amlish Munir, Muhammad ^a   Griffiths, Cameron ^a   Khan, Faisal M ^a   Stewart, Douglas A ^a   Russell, James A ^a   Daly, Andrew ^a   Storek, Jan ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acute GVHD; Antithymocyte globulin; Chronic GVHD

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RELAPSE; VIRUS REACTIVATION; WHOLE BODY RADIATION; ADOLESCENT; ANIMAL; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; PROCEDURES; RABBIT; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTILYMPHOCYTE SERUM; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RABBITS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904047623     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.04.007     Document Type: Article

References (33)

1. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
2. Remberger M., Sundberg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005, 90:931-938.
3. Remberger M., Sundberg B. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant 2009, 15:996-999.
4. Kim H.J., Min W.S., Cho B.S., et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009, 15:704-717.
5. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
6. Bacigalupo A., Lamparelli T., Milone G., et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants. Bone Marrow Transplant 2010, 45:385-391.
7. Russell J.A., Turner A.R., Larratt L., et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 2007, 13:299-306.
8. Bredeson C.N., Zhang M.J., Agovi M.A., et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:993-1003.
9. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
10. Socie G., Schmoor C., Bethge W.A., et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011, 117:6375-6382.
11. Mohty M., Labopin M., Balere M.L., et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia 2010, 24:1867-1874.
12. Waller E.K., Langston A.A., Lonial S., et al. Pharmacokinetics and pharmacodynamics of antithymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003, 9:460-471.
13. Rebellato L.M., Gross U., Verbanac K.M., Thomas J.M. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994, 57:685-694.
14. Preville X., Flacher M., LeMauff B., et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001, 71:460-468.
15. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007, 21:1387-1394.
16. Podgorny P.J., Ugarte-Torres A., Liu Y., et al. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transplant 2010, 16:915-926.
17. Russell J.A., Savoie M.L., Balogh A., et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGy total body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007, 13:814-821.
18. Hoegh-Petersen M., Roa L., Liu Y., et al. Low cytomegalovirus-specific T-cell counts at reactivation are associated with progression to high-level viremia or disease in seropositive recipients of hematopoietic cell grafts from seropositive but not seronegative donors. Cytotherapy 2012, 14:194-204.
19. +-selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2005, 11:609-618.
20. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
21. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
22. Lowe T., Bhatia S., Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007, 13:1121-1134.
23. Landgren O., Gilbert E.S., Rizzo J.D., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009, 113:4992-5001.
24. LaCorcia G., Swistak M., Lawendowski C., et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009, 87:966-974.
25. Popow I., Leitner J., Majdic O., et al. Assessment of batch to batch variation in polyclonal antithymocyte globulin preparations. Transplantation 2012, 93:32-40.
26. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 159:702-706.
27. Toutain P.L., Bousquet-Melou A. Plasma clearance. J Vet Pharmacol Ther 2004, 27:415-425.
28. Bosch M., Dhadda M., Hoegh-Petersen M., et al. Immune reconstitution after antithymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 2012, 14:1258-1275.
29. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
30. Korngold R., Sprent J. Negative selection of T cells causing lethal graft-versus-host disease across minor histocompatibility barriers: role of the H-2 complex. J Exp Med 1980, 151:1114-1124.
31. Podgorny P.J., Liu Y., Dharmani-Khan P., et al. Immune cell subset counts associated with graft-versus-host disease. Biol Blood Marrow Transplant 2014, 20:450-462.
32. Remberger M., Svahn B.M., Mattsson J., Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004, 78:122-127.
33. Joseph R.W., Couriel D.R., Komanduri K.V. Chronic graft-versus-host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care. J Support Oncol 2008, 6:361-372.